Dr. Richards on PARP Inhibition in Pancreatic Cancer

Donald A. Richards, MD, PhD
Published: Thursday, Sep 19, 2019



Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses PARP inhibition in patients with pancreatic cancer.

Patients with pancreatic cancer who have BRCA mutations are unable to repair double-strand breaks in the DNA. PARP inhibitors increase the number of single-strand breaks.

Patients with BRCA mutations have the lethal mutations accumulate. A normal cell without the BRCA mutation can repair itself, but the dual PARP inhibition in the DNA repair for patients with BRCA mutations leads to cell death.
SELECTED
LANGUAGE


Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses PARP inhibition in patients with pancreatic cancer.

Patients with pancreatic cancer who have BRCA mutations are unable to repair double-strand breaks in the DNA. PARP inhibitors increase the number of single-strand breaks.

Patients with BRCA mutations have the lethal mutations accumulate. A normal cell without the BRCA mutation can repair itself, but the dual PARP inhibition in the DNA repair for patients with BRCA mutations leads to cell death.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x